Precision BioSciences Inc expected to post a loss of $2.05 a share - Earnings Preview

Precision Biosciences

25/03/2024 12:43

* Precision BioSciences Inc  DTIL.OQ   DTIL.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 27
for the period ending December 31 2023
    * The Durham North Carolina-based  company is expected to
report a
17.8% increase in revenue to $12.481 million from $10.6 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Precision BioSciences
Inc is
for a loss of $2.05 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Precision
BioSciences Inc is $75.00​, above​ its last closing price
of $11.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -5.03       -4.87      -2.10     Beat    56.9
 Jun. 30 2023  -7.52       -7.32      -3.00     Beat    59
 Mar. 31 2023  -6.80       -6.78      -6.90     Missed  -1.8​
 Dec. 31 2022  -6.48       -6.22      -7.80     Missed  -25.3
 ​​Sep.        -7.63       -7.95      -6.60     Beat    17
 30 2022                                                
 Jun. 30 2022  -12.38      -12.33     -13.80    Missed  -11.9​
 Mar. 31 2022  -16.01      -16.23     -13.80    Beat    15
 Dec. 31 2021  -17.45      -14.19     -15.60    Missed  -9.9
 This summary was machine generated March 25 at 12:43 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)